Sugi Predict

Sugi Predict / Compounds / SCHEMBL465454

SCHEMBL465454

SCHEMBL465454

OCC(O)COC(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TK1 P04183 2/20 0.46
▸ KIF11 P52732 1/20 0.46
▸ CYP1A2 P05177 3/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ AGTR1 P30556 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ CTSK P43235 3/20 0.41
▸ CYP2C19 P33261 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ DUT P33316 1/20 0.41
▸ ACSS2 Q9NR19 1/20 0.39
▸ TSHR P16473 2/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ AR P10275 1/20 0.37
▸ CA1 P00915 2/20 0.36
▸ VDR P11473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6522822 1.00 TK1 (0.46) TK1KIF11CYP1A2KDM4EAGTR1
SCHEMBL2111572 0.90 KIF11 (0.50) TK1KIF11LMNACTSKCYP2C19
SCHEMBL3490250 0.87 KIF11 (0.49) TK1KIF11CYP1A2AGTR1LMNA
SCHEMBL15281845 0.87 KIF11 (0.49) TK1KIF11CYP1A2AGTR1LMNA
SCHEMBL4186681 0.85 TK1 (0.50) TK1KIF11LMNACTSKCYP2C19
SCHEMBL4186683 0.85 TK1 (0.50) TK1KIF11LMNACTSKCYP2C19
SCHEMBL4771137 0.83 TK1 (0.48) TK1KIF11LMNACTSKCYP2C19
SCHEMBL4917240 0.83 KIF11 (0.53) TK1KIF11CTSKCYP2C19DUT
SCHEMBL21087595 0.83 TK1 (0.48) TK1KIF11LMNACTSKCYP2C19
SCHEMBL9613450 0.83 TK1 (0.45) TK1KIF11LMNACTSKCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4466248-A1 LIPIDIC COMPOUNDS, AND USES THEREOF Sanofi (FR) 2024-11-27 — — EP disclosed
CN-118829624-A Lipid compound and use thereof 赛诺菲 2024-10-22 — — CN disclosed
US-20240201165-A1 NANOPORE-BASED ANALYSIS OF ANALYTES RIJKSUNIVERSITEIT GRONINGEN (NL) 2024-06-20 — — US disclosed
WO-2024091124-A1 NANOPORE-BASED ANALYSIS OF PROTEINS RIJKSUNIVERSITEIT GRONINGEN (NL) 2024-05-02 — — WO disclosed
EP-3389394-B1 FOOD PRODUCT FOR REGULATING LIPID METABOLITES AND METHODS MARS INC (US) 2024-02-21 — — EP disclosed
US-11877587-B2 Infant nutrition with hydrolysed protein, ionic calcium and palmitic acid SOCIETE DES PRODUITS NESTLE S.A. (CH) 2024-01-23 — — US disclosed
US-20230295097-A1 LIPIDIC COMPOUNDS COMPRISING AT LEAST ONE TERMINAL RADICAL OF FORMULA -NH-CX-A OR -NH-CX-NH-A, COMPOSITIONS CONTAINING THEM AND USES THEREOF SANOFI PASTEUR (FR) 2023-09-21 — — US disclosed
US-20230295097-A1 LIPIDIC COMPOUNDS COMPRISING AT LEAST ONE TERMINAL RADICAL OF FORMULA -NH-CX-A OR -NH-CX-NH-A, COMPOSITIONS CONTAINING THEM AND USES THEREOF SANOFI PASTEUR (FR) 2023-09-21 — — US disclosed
US-20230293447-A1 CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF SANOFI PASTEUR (FR) 2023-09-21 — — US disclosed
US-20230293447-A1 CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF SANOFI PASTEUR (FR) 2023-09-21 — — US disclosed
WO-1992003122-A1 PREPARATION FOR APPLICATION OF ACTIVE SUBSTANCES IN THE FORM OF MINIMUM-SIZED DROPLETS CEVC GREGOR (DE) 1992-03-05 — — WO disclosed
US-5047540-A Platelet Activating Factor Antagonists and Antitumor Agents SHIONOGI & CO., LTD. (JP) 1991-09-10 — — US disclosed
EP-0430078-A2 Steroids F. HOFFMANN-LA ROCHE AG (CH) 1991-06-05 — — EP disclosed
CN-1009931-B The method for preparing glycerol ether phosphatides HOFFMANN LA ROCHE (CH) 1990-10-10 — — CN disclosed
EP-0321296-A1 Lipid derivatives their preparation and use SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) 1989-06-21 — — EP disclosed
EP-0284314-A1 Langmuir-blodgett film aggregates K & V LICENCING OY (FI) 1988-09-28 — — EP disclosed
US-4694084-A Glycerol ether phosphatides HOFFMANN-LA ROCHE INC. (US) 1987-09-15 — — US disclosed
CN-85103123-A The method for preparing glycerol ether phosphatides — 1986-10-22 — — CN disclosed
EP-0154977-A2 Glycerin-ether phosphatides, their preparation and use F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1985-09-18 — — EP disclosed
EP-0094586-A2 Glycerol derivatives, process for preparing same and pharmaceutical composition containing same ONO PHARMACEUTICAL CO., LTD. (JP) 1983-11-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230293447-A1 CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF MTTP, CETP, LNPEP TK1 1696/4885KIF11 2133/4885CYP1A2 1682/4885
US-20230295097-A1 LIPIDIC COMPOUNDS COMPRISING AT LEAST ONE TERMINAL RADICAL OF FORMULA -NH-CX-A OR -NH-CX-NH-A, COMPOSITIONS CONTAINING THEM AND USES THEREOF PRDX5, ANXA5, PRDX1 TK1 1276/4885KIF11 3089/4885CYP1A2 1266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.